Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis
* Healing of duodenal ulcers
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Part of H. pylori eradication regimens
### Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. For maintenance, 20-40 mg once daily.
* **Duodenal Ulcers:** 40 mg orally once daily for up to 4 weeks.
* **H. pylori Eradication:** 40 mg orally twice daily, in combination with antibiotics and sometimes bismuth, for 7-14 days.
* **Pathological Hypersecretory Conditions:** 40 mg orally or IV twice daily. Doses can be increased as needed. Typical doses range from 40 mg to 120 mg twice daily. The maximum dose is generally considered 120 mg IV or 240 mg orally per day, divided into doses.
### Pediatric Dosing
* **GERD (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 years to 11 years):** 20-40 mg orally once daily for up to 8 weeks, depending on severity.
* **Erosive Esophagitis (5 years and older):** 40 mg orally once daily for up to 8 weeks.
*Note: Pediatric IV dosing is not established by FDA; consult institutional guidelines.*
### Dose Adjustments
* **Hepatic Impairment:** Maximum oral dose of 20 mg once daily. IV dose may also require reduction; consult prescribing information.
* **Renal Impairment:** No dose adjustment necessary.
### Contraindications
* Hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
### Adverse Effects
Common: Diarrhea, headache, dizziness, abdominal pain, nausea, flatulence.
Long-term use: Increased risk of C. difficile infection, bone fractures (hip, wrist, spine), vitamin B12 deficiency, hypomagnesemia.
### Key Drug Interactions
* **Clopidogrel:** Reduced antiplatelet effect. Avoid concurrent use if possible; consider alternative PPIs less likely to inhibit CYP2C19.
* **Methotrexate:** May increase methotrexate levels. Monitor and consider dose reduction.
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, digoxin. Monitor for decreased efficacy of these drugs.
* **CYP2C19 substrates:** Monitor for altered efficacy or toxicity.
### Monitoring
* Magnesium levels (especially with prolonged use > 1 year or concurrent diuretic use).
* Vitamin B12 levels (with prolonged use).
* Bone mineral density (consider in patients at risk for osteoporosis).
* For patients on concomitant therapies that interact.
### Clinical Pearls
* Pantoprazole is generally considered to have fewer CYP2C19 interactions than omeprazole or esomeprazole, making it a potentially preferred option in patients taking clopidogrel, though caution is still advised.
* Administer oral pantoprazole 30-60 minutes before a meal.
* IV administration should be given over 15 minutes or as an infusion over 15 minutes.
* IV formulation requires reconstitution and further dilution.
*Disclaimer: This information is intended for clinical use and does not substitute for comprehensive prescribing information. Always consult the most current official prescribing information and institutional guidelines for complete details.*
